

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Spectroscopic and Kinetic Studies of Interactions of Calf Spleen Purine Nucleoside Phosphorylase with 8-Azaguanine, and Its 9-(2-Phosphonylmethoxyethyl) Derivative

Jacek Wierzchowski<sup>a</sup>; Katarzyna Stępnia<sup>b</sup>; Agnieszka Bzowska<sup>b</sup>; David Shugar<sup>bc</sup>

<sup>a</sup> Department of Biophysics, University of Warmia and Mazury, Olsztyn, Poland <sup>b</sup> Department of Biophysics, University of Warsaw, Warsaw, Poland <sup>c</sup> Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

**To cite this Article** Wierzchowski, Jacek , Stępnia, Katarzyna , Bzowska, Agnieszka and Shugar, David(2005) 'Spectroscopic and Kinetic Studies of Interactions of Calf Spleen Purine Nucleoside Phosphorylase with 8-Azaguanine, and Its 9-(2-Phosphonylmethoxyethyl) Derivative', *Nucleosides, Nucleotides and Nucleic Acids*, 24: 5, 459 — 464

**To link to this Article:** DOI: 10.1081/NCN-200060004

**URL:** <http://dx.doi.org/10.1081/NCN-200060004>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SPECTROSCOPIC AND KINETIC STUDIES OF INTERACTIONS OF CALF SPLEEN PURINE NUCLEOSIDE PHOSPHORYLASE WITH 8-AZAGUANINE, AND ITS 9-(2-PHOSPHONYLMETHOXYETHYL) DERIVATIVE

**Jacek Wierchowski** □ *Department of Biophysics, University of Warmia and Mazury, Olsztyn, Poland*

**Katarzyna Stępnia and Agnieszka Bzowska** □ *Department of Biophysics, University of Warsaw, Warsaw, Poland*


**David Shugar** □ *Department of Biophysics, University of Warsaw, Warsaw, Poland and Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland*

□ *Spectroscopic and kinetic studies of interactions of calf spleen purine nucleoside phosphorylase with 8-azaguanine, an excellent fluorescent/fluorogenic substrate for the synthetic pathway of the reaction, and its 9-(2-phosphonylmethoxyethyl) derivative, a bisubstrate analogue inhibitor, were carried out. The goal was to clarify the catalytic mechanism of the enzymatic reaction by identification of ionic/tautomeric forms of these ligands in the complex with PNP.*

**Keywords** Purine Nucleoside Phosphorylase, Catalytic Mechanism, Enzyme-Ligand Complexes, 8-Azaguanine, Fluorescence

### INTRODUCTION

Purine nucleoside phosphorylase (PNP, E.C. 2.4.2.1), is a potential target for antimicrobial, antileukemic and antiparasitic therapies.<sup>[1]</sup> The enzyme catalyzes a reversible phosphorolysis of purine ribo- and 2'-deoxyribonucleosides, as follows:



The reaction mechanism involves an oxocarbenium intermediate in the transition state,<sup>[2]</sup> but controversy remains regarding protonation of the purine N(7),

Supported by Polish State Committee for Scientific Research KBN (grants 3P04A 035 24 and 3P04A 024 25).

Address correspondence to Jacek Wierchowski, Department of Biophysics, University of Warmia and Mazury, 4 Oczapowskiego St., Olsztyn 10-719, Poland; E-mail: jacek.wie@uwm.edu.pl

and, consequently, the endpoint of the reaction. If, as postulated by Fedorov et al.,<sup>[2]</sup> N(7) is protonated, the product purine must be released as the N(7)H tautomer. But, in the absence of protonation, the purine must adopt either an anionic form,<sup>[3]</sup> or be neutralized by proton transfer from the second product, ribose-1-phosphate.<sup>[4]</sup>

We here apply fluorescence spectroscopy to analyze complexes of calf spleen PNP with 8-azaguanine (8-azaG, Scheme 1), a fluorescent substrate for the reverse synthetic pathway of the reaction,<sup>[5,6]</sup> and its 9-(2-phosphonylmethoxyethyl) derivative<sup>[7]</sup> (PME-azaG, see Scheme 1), a bisubstrate analogue inhibitor,<sup>[8]</sup> with the aim to identify tautomeric/ionic structures of the bound ligands, using methodology similar to that applied previously to bacterial PNP.<sup>[9]</sup>

## EXPERIMENTAL

Calf spleen PNP from Sigma (18–34 units/mg), following desalting, was only minimally contaminated with phosphate ( $\leq 1 \mu\text{M}$ ), and PNP concentration was determined from the extinction of  $9.6 \text{ cm}^{-1}$  at 280 nm for a 1% solution.<sup>[10]</sup> 9-(2-Phosphonylmethoxyethyl)-8-azaguanine (PME-azaG) was synthesized by Holý et al.<sup>[7]</sup> Ribose-1-phosphate (R1P), 7-methylguanosine ( $\text{m}^7\text{Guo}$ ), 8-azaG, and xanthine oxidase were products of Sigma. All other chemicals were of the highest purity available. Concentrations of stock solutions of 8-azaG, PME-azaG, and  $\text{m}^7\text{Guo}$  were determined spectrophotometrically.<sup>[5,6,10]</sup>

Spectrophotometric measurements were carried out with Kontron (Austria) Uvikon-922, Uvikon-930, or Cary 3E (Varian) instruments, and fluorescence with a Perkin-Elmer LS-50 spectrofluorimeter (Norwalk, CT), all equipped with thermostatically controlled cell compartments. In fluorimetric measurements the spectral bandwidths were 2–5 nm for the entrance slit, and 3–15 nm for the exit slit. Fluorimetric titrations were performed and analyzed as elsewhere described.<sup>[6,11,12]</sup>

## Kinetic Procedures

With  $\text{m}^7\text{Guo}$  and 8-azaG as substrates, direct spectrophotometric assays were based on differences in molar extinctions between substrates and products:  $\Delta\epsilon = 4600 \text{ M}^{-1}\text{cm}^{-1}$  at 260 nm at pH 7.0 for  $\text{m}^7\text{Guo}$ <sup>[10]</sup> and  $\Delta\epsilon = 6500 \text{ M}^{-1}\text{cm}^{-1}$  at 260 nm and pH 7.0 for 8-azaG. For 8-azaG also fluorimetric method was employed.<sup>[5,6]</sup> The initial velocity data were fitted to the generalized kinetic equation:

$$\frac{V_{\max}}{V} = 1 + \frac{K_{m1}}{[S_1]} + \frac{K_{m2}}{[S_2]} + \frac{K_{12}}{[S_1][S_2]} \quad (1)$$

Inhibition of the enzyme by the bisubstrate analogue inhibitor PME-azaG was analyzed assuming a double competitive model (i.e., assuming only a binary enzyme-inhibitor complex):

$$\frac{V_{\max}}{V} = 1 + \frac{K_{m1}}{[S_1]} + \frac{K_{m2}}{[S_2]} + \frac{K_{12}}{[S_1][S_2]} \left( 1 + \frac{[I]}{K_i} \right) \quad (2)$$

where  $[I]$  is the inhibitor concentration and  $K_i$  the inhibition constant. With one of the substrates ( $S_2$ ) at constant concentration, it is possible to determine the apparent inhibition constants,  $K_i^{app}$ , by measuring initial rates with varying concentrations of the second substrate ( $S_1$ ) and the inhibitor. The thermodynamic value of the inhibition constant  $K_i$  is related to  $K_i^{app}$  by:

$$K_i^{app} = K_i \left( 1 + \frac{[S_2]}{K_{m2}} \right) \quad (3)$$

## RESULTS AND DISCUSSION


8-AzaG is a good substrate for the calf PNP in the reverse, synthetic pathway.<sup>[5]</sup> Kinetic parameters for this reaction, recently re-evaluated using desalted calf enzyme and phosphate-free buffers<sup>[6]</sup> are highly pH-dependent, the  $K_m$  increasing from 90  $\mu\text{M}$  at pH 5.9 to  $\sim 700$   $\mu\text{M}$  at pH 8, with virtually constant  $V_{max}$ . This behavior, contrasting with that of guanine, indicates that the monoanionic form of 8-azaG, predominating at pH  $> 7$  ( $pK_a$  6.5), is not a substrate for the enzyme.

The increased acidity of 8-azapurines, relative to the parent purines, results from high acidity of the triazole proton.<sup>[13]</sup> Therefore, the monoanionic form of 8-azaG bears a negative charge on the five-membered ring (Scheme 1), like that postulated in the Erion mechanism of PNP catalysis.<sup>[3]</sup> We conclude that inability of this form to react with PNP testifies against the model, and in favour a model postulating neutral purine as the substrate.

Neutral 8-azaG exist as a mixture of several tautomeric forms (Scheme 1), with N(9)H predominating in aqueous medium.<sup>[5]</sup> The compound is strongly fluorescent at  $\sim 390$  nm, but its fluorescence excitation spectrum is red-shifted by  $\sim 20$  nm relative to the UV absorption, indicating that this emission comes from a minor tautomer; i.e., N(8)H or N(7)H. To resolve which of these forms dominates when bound to the enzyme we examined fluorescence of the PNP/8-azaG complex.

Fluorimetric titration of calf PNP with 8-azaG with  $\lambda_{exc}$  315 nm shows a strongly fluorescent complex with  $\lambda_{max} \sim 370$  nm, with dissociation constants  $K_d$  of  $90 \pm 5$   $\mu\text{M}$  at pH 7.0, and  $\sim 450$   $\mu\text{M}$  at pH 7.7.<sup>[6]</sup> With excitation at 285 nm (Figure 1, left panel) significant quenching of protein fluorescence is additionally observed. The fluorescence excitation difference spectra, monitored with  $\lambda_{obs}$  370 nm, exhibit a maximum at  $\sim 280$  nm, which we interpret as a result of energy transfer from tryptophan to the ligand. But the entire spectrum is clearly red-shifted relative to both UV absorbance and fluorescence excitation of the free 8-azaG (Figure 1). It is also clearly distinct from that of the monoanion. These observations question both the N(9)H tautomer and the monoanion as the principal forms of 8-azaG in the complex with PNP.


PME-8azaG has been shown previously to bind to the calf PNP, leading to a highly fluorescent complex.<sup>[14]</sup> We selected this compound because of its fixed



SCHEME 1

tautomeric structure, which is spectrally similar to the N(9)H form of 8-azaG (Scheme 1).

Inhibition of phosphorolysis by PME-8azaG was studied at pH 7.0, with  $m^7$ Guo as a substrate reasonably following Michaelis-Menten kinetics.<sup>[10]</sup> Dixon plots displayed a competitive mode of inhibition (not shown), but, in accordance with Eq. 3, plots of  $K_i^{app}$  vs. fixed substrate concentrations were linear in the concentration range of 0.1–5 mM for phosphate ( $P_i$ ) and 20–300  $\mu$ M for  $m^7$ Guo, giving intercepts ( $K_i$ ) of  $(0.70 \pm 0.28) \mu$ M for  $P_i$ , and  $(0.98 \pm 0.21) \mu$ M for  $m^7$ Guo as fixed substrates, respectively.<sup>[6]</sup> In turn, we examined inhibition of the reverse synthetic reaction by PME-azaG, with 8-azaG and R1P as substrates, in phosphate-free buffer. As for the phosphorolytic pathway, an apparently competitive inhibition was observed, and the  $K_i^{app}$  values were markedly dependent on the second (fixed) substrate concentration. The calculated values of  $K_i = (1.9 \pm 0.3) \mu$ M, obtained



**FIGURE 1** Left panel: Comparison of fluorescence excitation (---) and emission (—) difference spectra, on titration of calf PNP with 8-azaG at pH = 6.15, with absorption (---) and fluorescence excitation (● ● ●) and emission (○ ○ ○) spectra of the neutral form of 8-azaG, and absorption spectrum (---) of the monoanion of 8-azaG. Active site concentration is 5.2  $\mu\text{M}$ , and ligand concentrations (—, bottom to top) are 2.7, 5.5, and 10.9  $\mu\text{M}$ . Conditions:  $\lambda_{\text{exc}}$  285 nm,  $\lambda_{\text{obs}}$  370 nm; spectral resolution 3/5 nm. Right panel: Fluorescence difference emission (—) and excitation (---) spectra of PNP/PME-azaG complex at pH = 7.0. Active site concentration is 6.5  $\mu\text{M}$ , and ligand concentrations (—, from bottom to top) are 2.3, 4.5, 5.9, 21.5  $\mu\text{M}$ . Conditions:  $\lambda_{\text{exc}}$  285 nm,  $\lambda_{\text{obs}}$  340 nm; spectral resolution 3/5 nm. Absorption (---) and fluorescence emission (○ ○ ○) spectra of PME-azaG are shown for comparison.

assuming a “double-competitive” model of inhibition (Eqs. 2 and 3), was independent of the fixed substrate concentration, consistent with competition of PME-azaG *vs.* both 8-azaG and RIP.

PME-azaG emits weakly at pH 7.0, but strongly as an anion ( $\text{pK}_{\text{a}}$  9.0). Fluorimetric titration of PNP with PME-azaG at pH 7.0 gave  $K_{\text{d}} = (0.6 \pm 0.3) \mu\text{M}$ , in agreement with kinetic results, and ligand emission at 340 nm increased about 10-fold upon binding (Figure 1, right panel). At first sight, this might be interpreted as preferential binding of the fluorescent anionic form. But the UV difference spectrum recorded during titration clearly does not resemble the UV spectral difference between the neutral and anionic species of PME-azaG.<sup>[6]</sup> Furthermore, the difference excitation spectrum resembles the UV spectrum of the neutral ligand (Figure 1), with  $\sim 5$  nm red shift, and clearly differs from that of the anion (not shown). We conclude that the ligand remains in the neutral form in the complex, and that enhancement of the emission of this form is observed. This neutral species is spectrally distinct from that of the bound 8-azaG, confirming that the latter does not adopt the N(9)H form.

The spectral properties of PNP/8-azaG and PNP/PME-azaG complexes, and in particular the previously unpublished fluorescence excitation difference spectra, support our conclusion<sup>[6]</sup> that 8-azaG is bound to PNP as a neutral N(7)H or N(8)H tautomer, and therefore question model of catalysis in which the purine base is bound to the enzyme as an anion. This model was based in part on the properties of the fluorescent PNP-guanine complex, interpreted as evidence of dissociation of Gua upon binding.<sup>[15]</sup> But the observed fluorescence of Gua complexed with PNP

may also originate from the neutral N(7)H form, which is known to emit intensely in rigid glasses at 140–160 K.<sup>[16]</sup> The reported strong binding of purines by PNP in the absence of phosphate<sup>[10,17]</sup> may lead to sufficient rigidity to enhance fluorescence yield of the bound N(7)H tautomer.

## REFERENCES

1. Bzowska, A.; Kulikowska, E.; Shugar, D. Purine nucleoside phosphorylases: properties, functions and clinical aspects. *Pharmacol. Ther.* **2000**, *88*, 349–425.
2. Fedorov, A.; Shi, W.; Kicska, G.; Fedorov, E.; Tyler, P.C.; Furneaux, R.H.; Hanson, J.C.; Gainsford, G.J.; Larese, J.Z.; Schramm, V.L.; Almo, S.C. Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. *Biochemistry* **2001**, *40*, 853–860.
3. Erion, M.D.; Stoeckler, J.D.; Guida, W.C.; Walter, R.L.; Ealick, S.E. Purine nucleoside phosphorylase. 2. Catalytic mechanism. *Biochemistry* **1997**, *36*, 11735–11748.
4. Tebbe, J.; Bzowska, A.; Wielgus-Kutrowska, B.; Schröder, W.; Shugar, D.; Saenger, W.; Koellner, G. Crystal structures of purine nucleoside phosphorylase (PNP) from *Cellulomonas sp.* and its implications of the molecular mechanism of trimeric PNPs. *J. Mol. Biol.* **1999**, *294*, 1239–1255.
5. Wierchowski, J.; Wielgus-Kutrowska, B.; Shugar, D. Fluorescence emission properties of 8-Azapurines and their nucleosides, and application to the kinetics of the reverse synthetic reaction of purine nucleoside phosphorylase. *Biochim. Biophys. Acta* **1996**, *1290*, 9–17.
6. Wierchowski, J.; Bzowska, A.; Stepniak, K.; Shugar, D. Interactions of calf spleen purine nucleoside phosphorylase with 8-azaguanine, and a bisubstrate analogue inhibitor: implications for the reaction mechanism. *Z. Naturforsch.* **2004**, *59c*, in press.
7. Holý, A.; Dvorakova, H.; Jindrich, J.; Masojdkova, M.; Budesinsky, M.; Balzarini, J.; Andrei, G.; De Clercq, E. Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. *J. Med. Chem.* **1996**, *39*, 4073–4088.
8. Kulikowska, E.; Bzowska, A.; Holý, A.; Magnowska, L.; Shugar, D. Antiviral acyclic nucleoside phosphonates as inhibitors of purine nucleoside phosphorylase. *Adv. Exp. Med. Biol.* **1998**, *431*, 747–752.
9. Kierdaszuk, B.; Modrak-Wójcik, A.; Wierchowski, J.; Shugar, D. Formycin A and its N-methyl analogues, specific inhibitors of *E. coli* purine nucleoside phosphorylase: induced tautomeric shift on binding to enzyme, and enzyme→ligand fluorescence resonance energy transfer. *Biochim. Biophys. Acta* **2000**, *1476*, 109–128.
10. Bzowska, A. Calf spleen purine nucleoside phosphorylase: complex kinetic mechanism, hydrolysis of 7-methylguanosine, and oligomeric state in solution. *Biochim. Biophys. Acta* **2002**, *1596*, 293–317.
11. Wielgus-Kutrowska, B.; Bzowska, A.; Tebbe, J.; Koellner, G.; Shugar, D. Purine nucleoside phosphorylase (PNP) from *Cellulomonas sp.*: physico-chemical properties, and binding of substrates determined by ligand-dependent enhancement of enzyme intrinsic fluorescence, and by protective effects of ligands on thermal inactivation of the enzyme. *Biochim. Biophys. Acta* **2002**, *1597*, 320–334.
12. Bzowska, A.; Koellner, G.; Wielgus-Kutrowska, B.; Stroh, A.; Raszewski, G.; Holý, A.; Steiner, T.; Frank, J. Crystal structure of calf spleen purine nucleoside phosphorylase with two full trimers in the asymmetric unit: important implications for the mechanism of catalysis. *J. Mol. Biol.* **2004**, *342*, 1015–1032.
13. Albert, A. Chemistry of 8-azapurines. *Adv. Heterocycl. Chem.* **1986**, *39*, 117–178.
14. Wierchowski, J.; Kulikowska, E.; Bzowska, A.; Holý, A.; Magnowska, L.; Shugar, D. Interactions of purine nucleoside phosphorylase with antiviral acyclic nucleoside phosphonate inhibitors—kinetic and emission studies. *Nucleosides Nucleotides* **1999**, *18*, 875–876.
15. Porter, D.J. Purine nucleoside phosphorylase. Kinetic mechanism of the enzyme from calf spleen. *J. Biol. Chem.* **1992**, *267*, 7342–7351.
16. Wilson, M.; Callis, P.R. Prototropic tautomerism and the apparent photophysics of adenine and guanine at 77K. *Photochem. Photobiol.* **1980**, *31*, 323–327.
17. Kline, P.C.; Schramm, V.L. Purine nucleoside phosphorylase. Inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-site reactivity. *Biochemistry* **1992**, *31*, 5964–5973.